04 May 2020
Visiongain has launched a new pharma report Canine Atopic Dermatitis Treatment Market Report 2020-2030: Forecasts by Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others), Mode of Administration (Tropical, Oral, Injectable), Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global Canine Atopic Dermatitis Treatment Market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that the market is projected to grow on account of growing concerns among the pet owners regarding the wellbeing of their pets. Additionally, rising pet ownerships coupled with growing investments by major players is anticipated to boost market growth further.
To access the data contained in this document please email firstname.lastname@example.org
Canine atopic dermatitis (CAD) is a genetically predisposed inflammatory and pruritic allergic skin disease with characteristic clinical features. It is associated most commonly with immunoglobin E (IgE) antibodies to environmental allergens.
Based on the product, the canine atopic dermatitis treatment market is segmented into glucocorticoids, antihistamines, immunosuppressants, MAbs, and others. In the year 2019, the glucocorticoids dominated the global market owing to its increased usage coupled with cheaper costs. Monoclonal antibody therapy is the fastest-growing therapeutic area in human medicine. In recent years, research has focused on how these therapies can be translated to animal health. Specifically, Zoetis has invested in bringing an innovative biological therapy to the treatment of canine atopic dermatitis.
North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to growing adoption rates of companion animals coupled with rising disposable income. Additionally, untapped nations in this region have been attracting investments by global players and this is expected to boost the Canine Atopic Dermatitis Treatment Market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Canine Atopic Dermatitis Treatment Market.
For instance, on 8th January 2020; Boragen – a boron-based discovery platform company – has signed an exclusive R&D agreement with the undisclosed firm to advance compounds that target atopic dermatitis in dogs. As part of the deal, the unnamed company will have an exclusive option to license lead compounds for development and commercialization in the animal health field.
The comprehensive market report features companies such as AB Science, Boehringer Ingelheim, Elanco, Kinderd Biosciences, Toray Industries, Virbac, Zoetis, Novartis among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.